{"Q": 1, "answer": "no", "rationale": "No intensifier or comparative adjective directly modifies a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_5724", "batch_size": 200, "batch_pos": 93, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 2, "answer": "no", "rationale": "The segment describes advantages of technology, not the threat's impact.", "method": "llm_batch", "batch_id": "batch_2_14192", "batch_size": 200, "batch_pos": 52, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 3, "answer": "no", "rationale": "The segment does not contain a moderate verb paired with significant scale or impact information.", "method": "llm_batch", "batch_id": "batch_3_13056", "batch_size": 200, "batch_pos": 3, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 4, "answer": "no", "rationale": "The segment contains no loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_11276", "batch_size": 200, "batch_pos": 192, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 5, "answer": "no", "rationale": "The quoted source reports advantages of technology without explicit calming language about the current situation.", "method": "llm_batch", "batch_id": "batch_5_19260", "batch_size": 200, "batch_pos": 184, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 6, "answer": "no", "rationale": "No minimiser + scale contrast found.", "method": "llm_batch", "batch_id": "batch_6_15168", "batch_size": 200, "batch_pos": 143, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 7, "answer": "no", "rationale": "No bare negation found.", "method": "llm_batch", "batch_id": "batch_7_11256", "batch_size": 200, "batch_pos": 132, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 8, "answer": "yes", "rationale": "The segment describes advantages of a technology related to capability ('offers advantages in efficacy, speed... scalability, and reliability') without active reassurance.", "method": "llm_batch", "batch_id": "batch_8_7888", "batch_size": 200, "batch_pos": 179, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
